Araştırma Makalesi
BibTex RIS Kaynak Göster

Nörofibromatozis tip 1 hastalarının radyolojik ve fenotopik değerlendirilmesi

Yıl 2018, Cilt: 10 Sayı: 4, 413 - 416, 01.12.2018
https://doi.org/10.21601/ortadogutipdergisi.417943

Öz

Amaç: Çocukluk çağı nörofibromatozis
tip 1 olgularımızın klinik ve radyolojik bulgularının değerlendirilmesi

Gereç ve Yöntem: 2013-2016 yılları arasında Sütçü
İmam Üniversitesi Tıp Fakültesi Çocuk Nöroloji Bilim Dalı’nda nörofibromatozis
tanısı ile takip ve tedavileri yapılan hastaların klinik ve radyolojij özellikleri
retrospektif olarak değerlendirildi.

Bulgular: Çalışma grubuna 21 çocuk dahil
edildi. Bunlardan 11’i erkek ve 10’u kızdı. Yaş ortalaması 10.41±3.05 yıl
saptandı. On dört (%28,6) olguda aile öyküsü mevcuttu. On bir (%52,3) hastada Lisch
nodülü ve 7 (%33,3) hastada koltukaltı çillenmesi görüldü. Olguların 5 (%23,8)’inde
nörofibrom vardı. Olguların hiçbirinde pleksiform nörofibrom saptanmadı. Dört (%19)
hastada skolyoz görülmüştür. Olguların 6’sında (%28,5) öğrenme güçlüğü vardı.







Sonuç: Nörofibromatozis tip 1’in erken
tanısı; ailelerin hastalık hakkında bilgilendirilmesi ve bu çocukların düzenli
klinik takibi ile tedavi edilebilir komplikasyonları önlemek açısından çok önemlidir. 

Kaynakça

  • Referans1. Carman KB, Yarar C, Ekici A, et al. Nörofibromatozis Tip 1: 49 Olgunun Değerlendirilmesi Haydarpasa Numune Med J 2017;57(3):157-160.
  • Referans2. Kresak JL, Walsh M. Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis. J Pediatr Genet 2016;5:98–104.
  • Referans3. Abramowicz A, Gos M. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease. Dev Period Med 2014;18:297–306.
  • Referans4. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988;45:575–8.
  • Referans5. Saltık S, Dönmezer B, Yüksel E, Çakı S, Ergüven M. Nörofibromatozis tip 1 hastalarında klinik ve kraniyal manyetik rezonans görüntüleme özellikleri. Türk Pediatri Arşivi 2005; 40: 94- 101.
  • Referans6. Cnossen MH, de Goede-Bolder A, van den Broek KM, et al. A prospective 10 year follow up study of patients with neurofibromatosis type 1. Arch Dis Child 1998;78:408–12.
  • Referans7. Bernier A, Larbrisseau A, Perreault S. Café-au-lait Macules and Neurofibromatosis Type 1: A Review of the Literature. Pediatr Neurol 2016;60:24–9.
  • Referans8. Köse G, Özaydın E, Hasançebi B, Güven A. Neurofibromatosis Type-1:Clinical Evaluation of 44 Patients. Türkiye Klinikleri J Pediatr 2008;17:89–95.
  • Referans9. Khosrotehrani K, Bastuji-Garin S, Zeller J, Revuz J, Wolkenstein P. Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort study of 378 patients. Arch Dermatol 2003;139:187–91.Referans10. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 2014;13:834–43.Referans11. Abdolrahimzadeh S, Plateroti AM, Recupero SM, Lambiase A. An Update on the Ophthalmologic Features in the Phakomatoses. J Ophthalmol 2016;2016:3043026.Referans12. López-Pisón J, Cuadrado-Martín M, Boldova-Aguar MC, Muñoz-Mellado A, Cabrerizo de Diago R, Peña-Segura JL. Neurofibromatosis in children. Our experience. Rev Neurol 2003;37:820–5.
  • Referans13. Vivarelli R, Grosso S, Calabrese F, et al. Epilepsy in neurofibromatosis 1. J Child Neurol 2003;18:338–42.
  • Referans14. Tedesco MA, Di Salvo G, Natale F, et al. The heart in neurofibromatosis type 1: an echocardiographic study. Am Heart J 2002;143:883–8.
  • Referans15. Griffiths PD, Blaser S, Mukonoweshuro W, et al. Neurofibromatosis bright objects in children with neurofibromatosis type 1: a proliferative potential ? Pediatrics 1999; 104: 49.
  • Referans16. DeBella K, Poskitt K, Szudek J, et al. Use of "unidentified bright objects" on MRI for diagnosis of neurofibromatosis 1 in children. Neurology 2000; 54: 1646- 51.
  • Referans17. Aoki SA, Barkovich AJ, Nishimura K. Neurofibromatosis types 1 and 2: cranial MR findings. Radiology 1989; 172: 527- 34.
  • Referans18. Goldstein SM, Curless RG, Donovan Post MJ, et al. A new sign of neurofibromatosis on magnetic resonance imaging of children. Arch Neurol 1989; 46: 1222- 4.
  • Referans19. Balestri P, Calistri L, Vivarelli R, et al. Central nervous system imaging in reevaluation of patients with neurofibromatosis type 1. Childs Nerv Syst 1993; 9: 448- 51.
  • Referans20. Özmen M. Nörokütan hastalıklar. İçinde: Neyzi O, Ertuğrul T (eds). Pediatri İstanbul: Nobel, 2002: 1368- 72.
  • Referans21. Rodrigues AC Jr, Ferraz-Filho JR, Torres US, et al. Is magnetic resonance spectroscopy capable of detecting metabolic abnormalities in neurofibromatosis type 1 that are not revealed in brain parenchyma of normal appearance? Pediatr Neurol. 2015;52(3):314-9.

Phenotypic and radiological evaluation of neurofibromatosis type 1 patients

Yıl 2018, Cilt: 10 Sayı: 4, 413 - 416, 01.12.2018
https://doi.org/10.21601/ortadogutipdergisi.417943

Öz

Aim: The aim of our study is to evaluate
the clinical and radiological features of children with neurofibromatosis type
1.

Material and Method: The patients who were followed
up and treated with neurofibromatosis type 1 in Department of Pediatric
Neurology at Sutcu Imam University between the years of 2013-2016 were
retrospectively evaluated clinically and radiologically.

Results: Twenty one children were
included in this study. Of those, 11 were boys and 10 were girls. Fourteen
cases (28.6 %) had a family history. The mean age of the children was 10.41±3.05
years. Lisch nodules were observed in 11 patients, and axillary freckling in 7
patients. There were neurofibromas in 5 cases (23.8%). Plexiform neurofibromas
were not detected in any of the cases. Scoliosis was seen in 4 patients (19%). Six
of the cases (28.5%) had learning difficulties.

Conclusion: Early diagnosis of NF-1 is very
important to inform families about the disease and prevent treatable
complications with regular follow-up of these children.


 

 















 

Kaynakça

  • Referans1. Carman KB, Yarar C, Ekici A, et al. Nörofibromatozis Tip 1: 49 Olgunun Değerlendirilmesi Haydarpasa Numune Med J 2017;57(3):157-160.
  • Referans2. Kresak JL, Walsh M. Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis. J Pediatr Genet 2016;5:98–104.
  • Referans3. Abramowicz A, Gos M. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease. Dev Period Med 2014;18:297–306.
  • Referans4. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988;45:575–8.
  • Referans5. Saltık S, Dönmezer B, Yüksel E, Çakı S, Ergüven M. Nörofibromatozis tip 1 hastalarında klinik ve kraniyal manyetik rezonans görüntüleme özellikleri. Türk Pediatri Arşivi 2005; 40: 94- 101.
  • Referans6. Cnossen MH, de Goede-Bolder A, van den Broek KM, et al. A prospective 10 year follow up study of patients with neurofibromatosis type 1. Arch Dis Child 1998;78:408–12.
  • Referans7. Bernier A, Larbrisseau A, Perreault S. Café-au-lait Macules and Neurofibromatosis Type 1: A Review of the Literature. Pediatr Neurol 2016;60:24–9.
  • Referans8. Köse G, Özaydın E, Hasançebi B, Güven A. Neurofibromatosis Type-1:Clinical Evaluation of 44 Patients. Türkiye Klinikleri J Pediatr 2008;17:89–95.
  • Referans9. Khosrotehrani K, Bastuji-Garin S, Zeller J, Revuz J, Wolkenstein P. Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort study of 378 patients. Arch Dermatol 2003;139:187–91.Referans10. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 2014;13:834–43.Referans11. Abdolrahimzadeh S, Plateroti AM, Recupero SM, Lambiase A. An Update on the Ophthalmologic Features in the Phakomatoses. J Ophthalmol 2016;2016:3043026.Referans12. López-Pisón J, Cuadrado-Martín M, Boldova-Aguar MC, Muñoz-Mellado A, Cabrerizo de Diago R, Peña-Segura JL. Neurofibromatosis in children. Our experience. Rev Neurol 2003;37:820–5.
  • Referans13. Vivarelli R, Grosso S, Calabrese F, et al. Epilepsy in neurofibromatosis 1. J Child Neurol 2003;18:338–42.
  • Referans14. Tedesco MA, Di Salvo G, Natale F, et al. The heart in neurofibromatosis type 1: an echocardiographic study. Am Heart J 2002;143:883–8.
  • Referans15. Griffiths PD, Blaser S, Mukonoweshuro W, et al. Neurofibromatosis bright objects in children with neurofibromatosis type 1: a proliferative potential ? Pediatrics 1999; 104: 49.
  • Referans16. DeBella K, Poskitt K, Szudek J, et al. Use of "unidentified bright objects" on MRI for diagnosis of neurofibromatosis 1 in children. Neurology 2000; 54: 1646- 51.
  • Referans17. Aoki SA, Barkovich AJ, Nishimura K. Neurofibromatosis types 1 and 2: cranial MR findings. Radiology 1989; 172: 527- 34.
  • Referans18. Goldstein SM, Curless RG, Donovan Post MJ, et al. A new sign of neurofibromatosis on magnetic resonance imaging of children. Arch Neurol 1989; 46: 1222- 4.
  • Referans19. Balestri P, Calistri L, Vivarelli R, et al. Central nervous system imaging in reevaluation of patients with neurofibromatosis type 1. Childs Nerv Syst 1993; 9: 448- 51.
  • Referans20. Özmen M. Nörokütan hastalıklar. İçinde: Neyzi O, Ertuğrul T (eds). Pediatri İstanbul: Nobel, 2002: 1368- 72.
  • Referans21. Rodrigues AC Jr, Ferraz-Filho JR, Torres US, et al. Is magnetic resonance spectroscopy capable of detecting metabolic abnormalities in neurofibromatosis type 1 that are not revealed in brain parenchyma of normal appearance? Pediatr Neurol. 2015;52(3):314-9.
Toplam 18 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Sağlık Kurumları Yönetimi
Bölüm Araştırma makaleleri
Yazarlar

Olcay Güngör

Gülay Güngör

Can Acıpayam

Yayımlanma Tarihi 1 Aralık 2018
Yayımlandığı Sayı Yıl 2018 Cilt: 10 Sayı: 4

Kaynak Göster

Vancouver Güngör O, Güngör G, Acıpayam C. Nörofibromatozis tip 1 hastalarının radyolojik ve fenotopik değerlendirilmesi. otd. 2018;10(4):413-6.

e-ISSN: 2548-0251

The content of this site is intended for health care professionals. All the published articles are distributed under the terms of

Creative Commons Attribution Licence,

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.